Hu Chengkai, Zhu Kai, Li Jun, Wang Chunsheng, Lai Lao
Department of Cardiac Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Shanghai Institute of Cardiovascular Disease, Shanghai 200032, China.
J Thorac Dis. 2017 Nov;9(11):4708-4722. doi: 10.21037/jtd.2017.10.63.
Aortic aneurysm (AA) is a lethal disease and presents a large challenge for surgeons in the clinic. Although surgical management remains the major choice of AA, operative mortality remains high. With advances in understanding of the mechanisms of AAs, molecular targets, such as matrix metalloproteinases (MMPs), D-dimer, and inflammation markers, including C-reactive protein, interleukins and phagocytes, are important in the pathology of development of AA. These markers may become important for improving the diagnostic quality and provide more therapeutic choices for treatment of AA. Although these new markers require long-term trials before they can be translated into the clinic, they can still be helpful in determining new directions. The main aim of this review is to discuss the current findings of molecular targets in progression of AA and discuss the potential application of these new targets for managing this disease.
主动脉瘤(AA)是一种致命疾病,给临床外科医生带来了巨大挑战。尽管手术治疗仍是AA的主要选择,但手术死亡率仍然很高。随着对AA发病机制认识的不断深入,分子靶点,如基质金属蛋白酶(MMPs)、D-二聚体,以及炎症标志物,包括C反应蛋白、白细胞介素和吞噬细胞,在AA的病理发展过程中具有重要意义。这些标志物对于提高诊断质量可能具有重要意义,并为AA的治疗提供更多的治疗选择。尽管这些新标志物在能够应用于临床之前需要进行长期试验,但它们仍有助于确定新的研究方向。本综述的主要目的是讨论AA进展过程中分子靶点的当前研究结果,并探讨这些新靶点在管理该疾病方面的潜在应用。